期刊
BIOMATERIALS
卷 233, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2019.119741
关键词
Organ-on-a-chip; Tissue engineering; Heart failure; Cardiac fibrosis; Human stem cell-derived cardiomyocytes; Disease modeling; Pirfenidone; Carvediolol; Losartan; Force of contraction; microRNA; Extracellular vesicles
资金
- Canadian Institutes of Health Research (CIHR), Institute of Circulatory and Respiratory Health [137352, PJT153160]
- Natural Sciences and Engineering Research Council (NSERC) [RGPIN 066212017]
- NSERC CREATE Training program in organ -on-a-chip engineering and entrepreneurship (TOeP)
- NSERC Canada Graduate Scholarships-Master's Program (CGS M)
- CIHR [137352]
- NSERC [4361172013, EGP 500666-16]
- Tier II Canada Research Chair in Vascular Cell and Molecular Biology
While interstitial fibrosis plays a significant role in heart failure, our understanding of disease progression in humans is limited. To address this limitation, we have engineered a cardiac-fibrosis-on-a-chip model consisting of a microfabricated device with live force measurement capabilities using co-cultured human cardiac fibroblasts and pluripotent stem cell-derived cardiomyocytes. Transforming growth factor-beta was used as a trigger for fibrosis. Here, we have reproduced the classic hallmarks of fibrosis-induced heart failure including high collagen deposition, increased tissue stiffness, BNP secretion, and passive tension. Force of contraction was significantly decreased in fibrotic tissues that displayed a transcriptomic signature consistent with human cardiac fibrosis/heart failure. Treatment with an anti-fibrotic drug decreased tissue stiffness and BNP secretion, with corresponding changes in the transcriptomic signature. This model represents an accessible approach to study human heart failure in vitro, and allows for testing anti-fibrotic drugs while facilitating the real-time assessment of cardiomyocyte function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据